Press Release

PharmCADD has been certified ‘Intellectual Property Management Enterprise’ from the Korean Intellectual Property Office.

PharmCADD has been certified ‘Intellectual Property Management Enterprise’ from the Korean Intellectual Property Office. 더 읽기"

PharmCADD showed proprietary AI technology at Medicine-Bio Forum 2022.

PharmCADD showed proprietary AI technology at Medicine-Bio Forum 2022. 더 읽기"

PharmCADD was selected into the KOREA AI STARTUP 100 list.

PharmCADD was selected into the KOREA AI STARTUP 100 list. 더 읽기"

PharmCADD participated in AI KOREA 2022.

PharmCADD participated in AI KOREA 2022. 더 읽기"

“AI” will accellerate the drug developement.

“AI” will accellerate the drug developement. 더 읽기"

PharmCADD won “2022 AI KOREA Awards” from The Ministry of Trade, Industry and Energy.

PharmCADD won “2022 AI KOREA Awards” from The Ministry of Trade, Industry and Energy. 더 읽기"

PharmCADD & ISU ABXIS jointly develop a medicine for the treatment of neurofibromatosis type 1 (NFI)

PharmCADD & ISU ABXIS jointly develop a medicine for the treatment of neurofibromatosis type 1 (NFI) 더 읽기"

“Break the New Drug development limits through AI based on Quantum Mechanics.”

“Break the New Drug development limits through AI based on Quantum Mechanics.” 더 읽기"

Top 50 Pharma-Bio Companies, Started Quantum Jump by developing New AI Drugs.

Top 50 Pharma-Bio Companies, Started Quantum Jump by developing New AI Drugs. 더 읽기"

Dr. Sangwook Wu introduced potential platform technologies.

Dr. Sangwook Wu introduced potential platform technologies. 더 읽기"